← Leaderboards
Keiichiro Kushiro
Mucommune, Llc
$7,357,377
Attributed
$7,357,377
Total exposure
13
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.2M · FY2021–25$5M$3.8M$2.5M$1.3M$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,357,377 · 13
By mechanism
R44$3,857,915 · 3
R43$2,812,587 · 8
R61$380,692 · 1
N43$306,183 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Prevent”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$141,293,697
- Kimberly Smith · Ppd Development Lp$115,671,664
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$112,282,390
- Beth Baseler · Leidos Biomedical Research, Inc.$100,071,064
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$76,895,673
Research focus
PreventDoseVaginaSafetyAntibodiesDesignVaginal RingWomanFormulationAnimal ModelAnimalsBindingEnsureCostProductionClinical ResearchMucous Body SubstanceSheepFemaleSmall Business Innovation Research GrantClinical DevelopmentPharmaceutical PreparationsPregnancyClinic
Grant awards (15)
Fast Dissolving MM008 Tablet for Instant On-Demand Non-Hormonal Contraception$1,130,880
R44 · FY2025 · HD · contact PI
IND-enabling development of MM-009, a reservoir-intravaginal ring for ultra-highrates of month-long lactic acid release to treat and prevent bacterial vaginosis$1,025,000
R44 · FY2025 · AI · contact PI
Development of MM010, a PEG-specific intervention that blocks allergic response and restores effective repeat dosing of peg-asparaginase in patients with acute lymphoblastic leukemia$409,732
R43 · FY2025 · CA · contact PI
Development of an ultrapotent anti-sperm antibody construct for non-hormonal contraception$380,692
R61 · FY2025 · HD · contact PI
Development and evaluation of a pegloticase biobetter for sustained suppressionof fructose-induced obesity$359,608
R43 · FY2025 · DK · contact PI
Engineering a physiologically-tuned reservoir intravaginal ring releasing lactic acid for the treatment and prevention of bacterial vaginosis$310,136
R43 · FY2025 · AI · contact PI
Sustained release of VRC07 from capsule-intravaginal ring for preventing HIV transmission$306,183
N43 · FY2025 · AI · contact PI
IND-enabling development of MM010, a PEG-specific intervention that blocks allergic response and restores repeated dosing for select PEGylated medicines impacted by anti-PEG antibody$291,458
R43 · FY2025 · AI · contact PI
IND-enabling development of MM010, a PEG-specific intervention that blocks allergic response and restores repeated dosing for select PEGylated medicines impacted by anti-PEG antibody$291,458
R43 · FY2024 · AI · contact PI
Highly Acidifying Intravaginal Rings with Lactobacillus Probiotics to Treat Bacterial Vaginosis$306,483
R43 · FY2023 · AI · contact PI
Capsule-intravaginal ring for sustained release of antibodies for non-hormonal contraception and vaginal protection against HIV$791,080
R44 · FY2022 · HD · contact PI
Fast dissolving antibody tablets for preventing vaginal HSV transmission$306,500
R43 · FY2022 · AI · contact PI
Development of a qualified pharmacokinetic bioassay to support preclinical and clinical studies of MM-008, a non-hormonal contraceptive antibody$277,713
R43 · FY2022 · HD · contact PI
User-based identification of preferred design features for MM008, a non-hormonal contraceptive vaginal ring$259,499
R43 · FY2022 · HD · contact PI
Capsule-intravaginal ring for sustained release of antibodies for non-hormonal contraception and vaginal protection against HIV$910,955
R44 · FY2021 · HD · contact PI